3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
3
Pancreatic Neoplasms
2
Pain, Postoperative
2
Agnosia
2
Vesico-Ureteral Reflux
1
Ureteral Neoplasms
1
Thymoma
1
Nephrolithiasis
1
Lymphedema
1
Lung Neoplasms
1
Liver Neoplasms
1
Leiomyoma
1
Laparoscopic Surgery
1
Kidney Neoplasms
1
Duodenal Neoplasms
1
Cerebrovascular Disorders
1
Interventions
pembrolizumab
6
cabozantinib
6
Nivolumab
5
Ipilimumab
5
Axitinib
5
Radiosurgery
3
Blood Specimen Collection
3
zimberelimab
2
lenvatinib
2
Ultrasonography
2
Radiotherapy
2
Biopsy
2
tislelizumab
1
polyethylene glycol 3350
1
pazopanib
1
palbociclib
1
orellanine
1
olaparib
1
gallium Ga 68 dotatate
1
fludarabine
1
cyclopropapyrroloindole
1
brodalumab
1
belzutifan
1
atezolizumab
1
anlotinib
1
adagrasib
1
Watchful Waiting
1
Vincristine
1
Therapeutics
1
Temozolomide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Kidney Neoplasms
×
Bupivacaine
×
Clear all
NCT06349668
2026-02-05
SMILe
University Hospital, Linkoeping
Phase 3
Recruiting
220 enrolled